The effects of childhood cancer therapy on male reproductive function depend on many factors, including the boy’s age at the time of cancer therapy, the specific type and location of the cancer, and the treatment that was given. It is important to understand how the male reproductive system functions and how it may be affected by therapy given to treat cancer during childhood.

The male reproductive system

The male reproductive system contains many structures and is controlled by the pituitary gland in the brain. The testicles are located in the scrotum (the loose pouch of skin that hangs behind the penis). The testicles are made up of Leydig cells (cells that produce the male hormone - testosterone) and germ cells (cells that produce sperm). When a boy enters puberty, the pituitary gland in the brain releases two hormones (FSH and LH) that signal the testicles to begin producing sperm and testosterone. As puberty progresses, testosterone causes deepening of the voice, enlargement of the penis and testicles, growth of facial and body hair, and muscular development of the body.

How does cancer therapy affect the male reproductive system?

Cancer therapy can cause infertility (the inability to initiate a pregnancy). Infertility can occur following treatment with certain types of chemotherapy, radiation to the brain or testicles, or surgery involving the male reproductive system.

Another possible effect of cancer therapy is testosterone deficiency, also known as "hypogonadism" or "Leydig cell failure." When this occurs, the testicles are unable to produce enough of the male hormone, testosterone. If this happens to a young boy, he will not be able to go into puberty without the help of hormones prescribed by a doctor. If it develops after puberty, a man will need testosterone therapy to maintain muscular development, bone and muscle strength, proper distribution of body fat, sex drive, and the ability to have erections.
What are the causes of male reproductive problems after childhood cancer treatment?

Chemotherapy of the "alkylator" type (such as cyclophosphamide, nitrogen mustard and procarbazine) may cause infertility. The total dose of alkylating chemotherapy used during cancer treatment is important in determining the likelihood of damage to sperm-producing cells. The higher the total dose, the more potential for developing infertility. Very high doses can occasionally cause testosterone deficiency. If alkylating chemotherapy was used in combination with radiation, the risk of infertility is increased, and the possibility of testosterone deficiency also exists.

Radiation therapy can affect testicular function in two ways:

- **Radiation aimed directly at or near the testicles.** The sperm-producing cells (germ cells) are very sensitive to the effects of radiation therapy. Most males who receive radiation to the testicles at doses of 3 to 6 Gy (300 to 600 cGy/rads) or higher will be infertile. The testosterone producing cells are more resistant to the effects of radiation and chemotherapy, but if testicular radiation was given in doses of 20 Gy (2000 cGy/rads) or higher, the Leydig cells may stop functioning, resulting in testosterone deficiency (in addition to infertility).

- **Radiation to the pituitary gland in the brain.** Brain radiation can result in damage to the pituitary gland, leading to low levels of the hormones (FSH and LH) needed to signal the testicles to make sperm and testosterone. Males with low levels of these hormones will need to take testosterone for the rest of their lives. However, it is sometimes possible for these men to regain fertility with the use of specialized hormone treatments. Men who have infertility as a result of brain radiation and wish to achieve fertility should see a fertility specialist.

Surgery that involves removal of both testicles (bilateral orchiectomy) will result in infertility and testosterone deficiency. Pelvic surgery, such as retroperitoneal lymph node dissection (RPLD), or spinal surgery sometimes results in nerve damage that may prevent the ejaculation of sperm. Removal of the prostate or bladder may result in difficulties achieving an erection and/or ejaculation. In these situations, sperm production may be unaffected and fertility may still be possible by using specialized techniques, such as sperm harvesting and artificial insemination. If fertility is desired, consultation with a fertility specialist is recommended.
What types of cancer therapy increase the risk of problems with the male reproductive system?

- Chemotherapy - the class of drugs called "alkylators" can cause infertility when given in high doses. Very high doses may occasionally cause testosterone deficiency. Examples of these drugs are:
  - Alkylating agents:
    - Busulfan
    - Carmustine (BCNU)
    - Chlorambucil
    - Cyclophosphamide (Cytoxan™)
    - Ifosfamide
    - Lomustine (CCNU)
    - Mechlorethamine (nitrogen mustard)
    - Melphalan
    - Procarbazine
    - Thiotepa
  - Heavy metals:
    - Carboplatin
    - Cisplatin
  - Non-classical alkylators:
    - Dacarbazine (DTIC)
    - Temozolomide

- **Radiation therapy** to any of the following areas may cause infertility.
  - Testicles
  - Pelvis (including iliac/inguinal/femoral, bladder, prostate, total nodal, and "inverted Y" fields)
  - TBI (total body irradiation)
  - Head/brain (cranial) - if dose was 40 Gy (4000 cGy/rads) or higher

In addition to causing infertility, high doses of radiation to the testicles or pelvis (usually 20 Gy or higher) or brain (usually 40 Gy or higher) may also cause testosterone deficiency.

- **Surgeries** that may cause infertility or disrupt normal sexual functioning include:
  - Removal of both testicles (this surgery will always result in infertility)
  - Retroperitoneal lymph node dissection (RPLD)
  - Removal of tumor in the retroperitoneal area
  - Cystectomy (removal of the bladder)
■ Prostatectomy (removal of the prostate)
■ Spinal surgery
■ Removal of tumor near the spinal cord

In addition, removal of both testicles will result in infertility and testosterone deficiency.

What monitoring is recommended?
Males whose treatment places them at risk for problems with the reproductive system should have a yearly check-up that includes careful evaluation of their hormone and puberty status. Blood may be tested for hormone levels (FSH, LH, and testosterone). If any problems are detected, a referral to an endocrinologist (hormone specialist), urologist (specialist in the male reproductive organs) and/or fertility specialist may be recommended. Boys who have had both testicles removed should have regular check-ups with an endocrinologist starting at about age 11.

What can be done for testosterone deficiency?
Males with low testosterone levels should receive testosterone replacement therapy. Testosterone is available in several forms, including skin patches, injections, and topical gel. Your endocrinologist will determine which form of therapy is best for you.

How will I know if I am infertile?
Infertility is not related to sexual function. Some men with infertility may notice a decrease in the size or firmness of the testicles, but in others, there are no physical indications of infertility.

Males who had surgical removal of both testicles will not be able to make sperm, and infertility will be permanent. In other males, the only certain way to check for sperm production is to have a semen analysis performed. This test checks the appearance, movement and concentration of sperm in the semen. A semen analysis that shows azoospermia (no sperm in the semen sample) on more than one sample is an indicator of infertility.

Sterility following radiation is likely permanent. However, recovery of sperm production may occur months or years after the completion of chemotherapy in some men. For others, chemotherapy damage may be permanent. It is not possible to determine if sperm production will resume, especially if chemotherapy ended only a few years prior to the semen analysis. For this reason, always assume that you can make someone pregnant unless you are absolutely sure that you cannot!!
When should I get a semen analysis?

Any sexually mature male who is concerned about fertility should have a semen analysis performed. Most hospitals with adult services will be able to perform a semen analysis. Not all insurance companies cover the cost of this analysis, so you should check with your insurance company to be sure, or check with the hospital or clinic regarding the costs of this procedure. If the semen analysis results are within normal limits, natural conception can occur.

What if the sperm count is low?

If the results show no sperm (azoospermia) or very low sperm counts (oligospermia), the test should be repeated several times. Sperm recovery following chemotherapy may take as long as 10 years, so if you have had chemotherapy that may cause low sperm counts, it may be important to check periodically over several years. Also, men’s sperm counts vary considerably from day to day, so sub-normal test results may improve if additional samples are checked after waiting a month or two. Sperm production and quality may continue to improve as more time passes from the chemotherapy treatment.

Men who have low sperm counts cannot rely on this to prevent pregnancy. Pregnancy can occur with low sperm counts. Some method of birth control must be used if pregnancy is not desired.

If pregnancy is desired, men with low sperm counts may benefit from assisted reproductive techniques such as Intra-Cytoplasmic Sperm Injection (ICSI), a form of in vitro fertilization. A consultation with an infertility specialist is helpful in order to obtain further information regarding these options.

What are my options if there are no sperm in the semen analysis?

If semen analysis shows no sperm (azoospermia), and children are desired, a consultation with a doctor who specializes in male infertility should be obtained. Medical advancements dealing with male infertility are being made. Recently, surgeons have been able to locate areas of active sperm production in the testes of men who have no sperm on semen analysis. Surgical harvesting of the sperm has resulted in pregnancies with techniques devised for men with absent or very low sperm counts. Occasionally, azoospermia may be unrelated to chemotherapy altogether, and treatment for another disorder may be indicated.
Other good options for males who produce no sperm include donor insemination or adoption. Donor insemination (DI) uses sperm from another male, either from a known or anonymous donor. DI results in pregnancy with a child that is biologically related only to the mother. Additional options may include adoption of a biologically unrelated child or child-free living.

**How do I use the sperm cryopreserved before treatment started?**

Options for using banked sperm depend on the amount and quality of material saved. Men who banked sperm prior to cancer treatment will need to work with a doctor specializing in reproductive medicine, so that the cryopreserved (frozen) sperm can be used in an optimal manner.

**What if only one testicle was surgically removed?**

Although fertility and testosterone production are not usually affected if only one testicle was surgically removed, you should take precautions to protect the remaining testicle from injury by always wearing an athletic supporter with a protective cup when participating in any activities that may potentially cause injury to the groin area (such as contact sports, baseball, etc.). If your remaining testicle was treated with radiation, or if you received chemotherapy that can affect testicular function, the effects of these treatments are the same as discussed above.

**What are the risks if pregnancy occurs after childhood cancer treatment?**

Fortunately, in most cases, there is no increased risk of cancer or birth defects in children born to childhood cancer survivors. In rare cases, if the type of cancer in childhood was a genetic (inherited) type, then there may be a risk of passing that type of cancer on to a child. You should check with your oncologist if you are not sure whether the type of cancer you had was genetic.
Additional health information for childhood cancer survivors is available at www.survivorshipguidelines.org

Note: Throughout this Health Links series, the term "childhood cancer" is used to designate pediatric cancers that may occur during childhood, adolescence, or young adulthood. Health Links are designed to provide health information for survivors of pediatric cancer, regardless of whether the cancer occurred during childhood, adolescence, or young adulthood.

Disclaimer and Notice of Proprietary Rights

Introduction to Late Effects Guidelines and Health Links: The “Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers” and accompanying “Health Links” were developed by the Children's Oncology Group as a collaborative effort of the Late Effects Committee and Nursing Discipline and are maintained and updated by the Children's Oncology Group's Long-Term Follow-Up Guidelines Core Committee and its associated Task Forces.

For Informational Purposes Only: The information and contents of each document or series of documents made available from by the Children's Oncology Group relating to late effects of cancer treatment and care or containing the title “Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers” or the title “Health Link”, whether available in print or electronic format (including any digital format, e-mail transmission, or download from the website), shall be known hereinafter as “Informational Content”. All Informational Content is for informational purposes only. The Informational Content is not intended to substitute for medical advice, medical care, diagnosis or treatment obtained from a physician or health care provider.

To cancer patients (if children, their parents or legal guardians): Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition and do not rely on the Informational Content. The Children's Oncology Group is a research organization and does not provide individualized medical care or treatment.

To physicians and other healthcare providers: The Informational Content is not intended to replace your independent clinical judgment, medical advice, or to exclude other legitimate criteria for screening, health counseling, or intervention for specific complications of childhood cancer treatment. Neither is the Informational Content intended to exclude other reasonable alternative follow-up procedures. The Informational Content is provided as a courtesy, but not intended as a sole source of guidance in the evaluation of childhood cancer survivors. The Children's Oncology Group recognizes that specific patient care decisions are the prerogative of the patient, family, and healthcare provider.

No endorsement of any specific tests, products, or procedures is made by Informational Content, the Children's Oncology Group, or affiliated party or member of the Children's Oncology Group.

No Claim to Accuracy or Completeness: While the Children's Oncology Group has made every attempt to assure that the Informational Content is accurate and complete as of the date of publication, no warranty or representation, express or implied, is made as to the accuracy, reliability, completeness, relevance, or timeliness of such Informational Content.

No Liability on Part of Children's Oncology Group and Related Parties/ Agreement to Indemnify and Hold Harmless the Children’s Oncology Group and Related Parties: No liability is assumed by the Children's Oncology Group or any affiliated party or member thereof for damage resulting from the use, review, or access of the Informational Content. You agree to the following terms of indemnification: (i) “Indemnified Parties” include authors and contributors to the Informational Content, all officers, directors, representatives, employees, agents, and members of the Children's Oncology Group and affiliated organizations; (ii) by using, reviewing, or accessing the Informational Content, you agree, at your own expense, to indemnify, defend and hold harmless Indemnified Parties from any and all losses, liabilities, or damages (including attorneys’ fees and costs) resulting from any and all claims, causes of action, suits, proceedings, or demands related to or arising out of use, review or access of the Informational Content.

Proprietary Rights: The Informational Content is subject to protection under the copyright law and other intellectual property law in the United States and worldwide. The Children’s Oncology Group retains exclusive copyright and other right, title, and interest to the Informational Content and claims all intellectual property rights available under law. You hereby agree to help the Children’s Oncology Group secure all copyright and intellectual property rights for the benefit of the Children’s Oncology Group by taking additional action at a later time, action which could include signing consents and legal documents and limiting dissemination or reproduction of Informational Content.